Ally Bridge Group (NY) LLC
Ally Bridge Group (NY) LLC reported 25 holdings worth US$113M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Ally Bridge Group (NY) LLC reported 25 holdings worth US$113M as of Jun 30, 2026. Largest: Minerva Neurosciences, Inc, Promis Neurosciences Inc. and First Tracks Biotherapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 25
- Value as reported
- US$113M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Minerva Neurosciences, Inc | 2.18M | US$12.1M | 10.7% |
| Promis Neurosciences Inc. | 620K | US$8.16M | 7.2% |
| First Tracks Biotherapeutics, Inc. | 284K | US$5.72M | 5.1% |
| Axsome Therapeutics, Inc. | 16,493 | US$4.04M | 3.6% |
| Assembly Biosciences, Inc. | 140K | US$3.85M | 3.4% |
| Whitehawk Therapeutics, Inc. | 818K | US$3.75M | 3.3% |
| Edgewise Therapeutics, Inc. | 83,300 | US$3.38M | 3.0% |
| Climb Bio, Inc. | 249K | US$3.25M | 2.9% |
| Kura Oncology, Inc. | 290K | US$3.18M | 2.8% |
| Cytomx Therapeutics, Inc. | 775K | US$2.91M | 2.6% |
| Avalo Therapeutics, Inc. | 150K | US$2.77M | 2.5% |
| Palisade Bio, Inc. | 1.23M | US$2.57M | 2.3% |
| Solid Biosciences Inc. | 256K | US$2.56M | 2.3% |
| An2 Therapeutics, Inc. | 526K | US$2.55M | 2.3% |
| Perspective Therapeutics, Inc. | 744K | US$2.54M | 2.2% |
| Ideaya Biosciences, Inc. | 67,500 | US$2.52M | 2.2% |
| Inventiva Sa | 635K | US$2.4M | 2.1% |
| Alumis Inc. | 76,459 | US$2.15M | 1.9% |
| Ovid Therapeutics Inc. | 625K | US$1.68M | 1.5% |
| Eupraxia Pharmaceuticals, Inc. | 252K | US$1.67M | 1.5% |
| Ibio, Inc. | 390K | US$683K | 0.60% |
| Traws Pharma, Inc. | 786K | US$663K | 0.59% |
| Praxis Precision Medicines, Inc. | 0 | US$0 | 0.00% |
| Relmada Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Tarsus Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Abivax Sa | 0 | US$0 | 0.00% |
| Capricor Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Inhibikase Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related